Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 16Carcinoma, Non-Small-Cell Lung 7Rectal Neoplasms 6Colorectal Neoplasms 6Pancreatic Neoplasms 5Lung Neoplasms 5Colonic Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Carcinoma, Renal Cell 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasm Metastasis 3Melanoma 3Lymphoma, Follicular 3Head and Neck Neoplasms 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms, Male 3Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Liver Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Kidney Neoplasms 2Immunoblastic Lymphadenopathy 2

Interventions

tocotrienol, delta 1Surgical Procedures, Operative 1Sulindac 1Immunohistochemistry 1Erlotinib Hydrochloride 1Congresses as Topic 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Intraductal Neoplasms × Immunohistochemistry × Clear all
NCT00482625 2014-10-16

Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 8 charts
Gastrointestinal

Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡